Acetyl-L-Carnitine (ALCAR) — Research Profile

ALCAR is the acetylated form of L-Carnitine, which allows it to cross the blood-brain barrier. While L-Carnitine primarily supports fat metabolism and cardiovascular health, ALCAR targets the brain — supporting acetylcholine production, neuronal energy, and neuroprotection. Choose ALCAR for cognitive or neurological goals; choose L-Carnitine or LCLT for exercise and heart health.

A 2018 meta-analysis of 12 RCTs (n=791) published in Psychosomatic Medicine ^[1] found ALCAR significantly reduced depressive symptoms. It was comparable in efficacy to standard antidepressants but with fewer side effects. It may work by enhancing mitochondrial energy production in neurons and supporting acetylcholine and monoamine neurotransmitter systems.

Take ALCAR in the morning or early afternoon, as it can have mild stimulatory effects that may interfere with sleep. Most studies used divided doses (e.g., 500 mg three times daily or 1 g twice daily). It can be taken with or without food, though an empty stomach may improve absorption.

Acetyl-L-carnitine is itself a specific form of carnitine, and it is the form used in the trials targeting brain-related outcomes such as cognition, mood, and neuropathic pain ^[1][3]. It is sold mainly as oral capsules or powder, and no trial has shown one oral preparation to outperform another. For non-neurological goals like general carnitine status, plain L-carnitine has been the more commonly studied form.

The best-supported effects are modest reductions in depressive symptoms (meta-analysis of 12 RCTs, SMD -1.10 versus placebo, strongest in older adults) ^[1], small cognitive gains in mild cognitive impairment and early Alzheimer's at 1.5-3.0 g/day (effect size about 0.20) ^[3], and reduced pain in peripheral neuropathy, chiefly diabetic (mean VAS reduction about 1.2 points). Evidence is weaker elsewhere; for multiple sclerosis fatigue a systematic review found insufficient evidence of benefit ^[4].

There is no recommended daily allowance because the body synthesizes its own carnitine, so dosing is trial-based. Cognitive and Alzheimer's studies used 1.5-3.0 g/day ^[3], the multiple sclerosis fatigue trial used 2 g/day ^[4], and general supplemental carnitine intakes span roughly 3 mg to 5,000 mg according to the NIH Office of Dietary Supplements. Most demonstrated clinical benefit fell in the 1.5-3 g/day range ^[3].

No head-to-head trial has compared times of day for ALCAR, so an optimal time is not established. Studies focused on the total daily dose, commonly 1.5-3 g, rather than on timing ^[3]. Taking it with food may reduce the nausea and abdominal cramping that carnitine can cause at higher intakes.

The most common effects, reported by the NIH Office of Dietary Supplements at intakes around 3 g/day, are nausea, vomiting, abdominal cramps, diarrhea, and a fishy body odor. In peripheral neuropathy trials, reported events included headache, paresthesia, and gastrointestinal upset, with no severe adverse events attributed to ALC. In depression trials, adverse effects were less frequent than with antidepressant comparators ^[1].

The NIH Office of Dietary Supplements documents that certain anticonvulsants - valproic acid, phenytoin, phenobarbital, and carbamazepine - lower blood carnitine levels, and that pivalate-conjugated antibiotics can deplete carnitine with chronic use. These are cases of the drug affecting carnitine status; well-documented interactions in which ALCAR alters a medication's effect are limited. Anyone taking seizure medication should be cautious with carnitine supplements given this documented depletion effect.

The clearest medical need is in people who cannot maintain carnitine levels - those with genetic carnitine-transporter disorders, end-stage renal disease or hemodialysis, and premature infants - where the NIH Office of Dietary Supplements notes supplementation corrects deficiency. Among discretionary uses with supporting trials, ALCAR is most reasonable for older adults with depressive symptoms ^[1], people with mild cognitive impairment or early Alzheimer's ^[3], and patients with diabetic peripheral neuropathy pain. Healthy people who eat meat generally synthesize and obtain enough carnitine and have little demonstrated need.

Onset depends on the target outcome. In a meta-analysis of mild cognitive impairment and early Alzheimer's using 1.5-3.0 g/day, an advantage over placebo was already measurable at the first assessment at 3 months and increased with longer treatment ^[3]. Depression and neuropathic-pain trials ran over weeks to months rather than days, so ALCAR is not an acute same-day supplement ^[1].

Controlled cognitive-decline trials dosed 1.5-3.0 g/day for 3 to 12 months and reported ALCAR was well tolerated ^[3]. The NIH Office of Dietary Supplements notes carnitine has no established tolerable upper intake level, and that intakes around 3 g/day can cause fishy body odor and gastrointestinal upset. Continuous use beyond about a year has not been well characterized in trials.

There is no established tolerable upper intake level for carnitine, but the NIH Office of Dietary Supplements reports that intakes around 3 g/day can cause nausea, vomiting, abdominal cramps, diarrhea, and a fishy body odor. Carnitine is also metabolized to TMAO, a compound associated with cardiovascular risk, and can worsen muscle weakness in people with uremia and seizures in those with seizure disorders. Most clinical trials stayed within the 1.5-3 g/day range ^[3].

No supplement pairing has been shown in trials to outperform ALCAR taken alone; the meta-analyses supporting its use in depression, cognition, and neuropathic pain all tested it as a single agent ^[1][3]. Because carnitine is converted to TMAO more in meat-eaters than vegetarians, there is no proven advantage to stacking it with other TMAO precursors. No dangerous supplement-supplement interaction is documented, but neither is any added benefit from combining.

Acetyl-L-carnitine is a single defined molecule, so there is no botanical extract or percentage to standardize; the key is that the label reads 'acetyl-L-carnitine' (or ALCAR) rather than plain L-carnitine or L-carnitine-L-tartrate, which are distinct forms studied for different purposes. Confirm it specifies the L-form. Third-party purity and identity testing is the main quality signal, since ALCAR has no active ingredient to titrate.